# Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

> **NCT06793553** · PHASE2 · RECRUITING · sponsor: **Japan Breast Cancer Research Group** · enrollment: 106 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Induction therapy

## Key facts

- **NCT ID:** NCT06793553
- **Lead sponsor:** Japan Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-13
- **Primary completion:** 2026-03-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793553, "Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06793553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*